Ontology highlight
ABSTRACT:
SUBMITTER: DeStefano CB
PROVIDER: S-EPMC5900827 | biostudies-literature | 2018 May
REPOSITORIES: biostudies-literature
DeStefano Christin B CB Hourigan Christopher S CS
Therapeutic advances in hematology 20180327 5
While the past decade has seen a revolution in understanding of the genetic and molecular etiology of the disease, in clinical practice, initial therapy for acute myeloid leukemia (AML) patients has been a relatively straightforward choice between intensive combination cytotoxic induction therapy as used for decades or less-intensive hypomethylating therapy. The year 2017, however, witnessed US Food and Drug Administration approvals of midostaurin, enasidenib, gemtuzumab ozogamicin and CPX-351 f ...[more]